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Arsenic trioxide (As2O3) has been found effective in the treatment in the treatment of
acute promyelocytic leukemia (APML). Most studies with As2O3 involve patients with
APML who have relapsed following standard therapy. Between January 1998 and July
2000, 14 patients were recruited for an ongoing trial of As2O3 in the treatment of newly
diagnosed APML. Arsenic trioxide was administered at a dose of 10 mg/day until com-
plete remission (CR) was achieved. Afterward, a consolidation course and a maintenance
schedule consisting of As2O3 as a single agent were administered over 6 months. There
were 3 early deaths related to intra-cerebral hemorrhage: two on day 3 and one on day 4.
Of the 11 evaluable patients, one died on day 21 secondary to uncontrolled sepsis, while
the remaining 10 (91%) have attained CR. The average time to CR was 52.3 days (range:
34–70 days). One patient developed an isolated central nervous system (CNS) relapse
and subsequently went into a second CR following therapy with triple intrathecal che-
motherapy, cranial irradiation, and an additional 4-week course of systemic As2O3. This
patient, as well as the remaining nine, has continued to remain in CR at a median follow
up of 15 months (range: 2−33 months). Eight out of 10 patients achieved molecular
remission at variable periods during their consolidation and maintenance schedules. One
patient developed an ATRA syndrome and was administered daunorubicin (40 mg/day)
for 2 days. The side effects with this therapy were minimal and did not require cessation
of therapy in any patient. There was no significant hepatic toxicity. In our experience,
arsenic trioxide is effective in inducing and maintaining remission in patients with APML
with minimal side effects. The optimal regimen and total dose required need to be de-
fined. Am. J. Hematol. 70:292–299, 2002. © 2002 Wiley-Liss, Inc.
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INTRODUCTION
Arsenical compounds were used as early as 2000 B.C.,
both as a medicine and as a poison [1]. In 1931, Forkner
and Scott used Fowler’s solution in the treatment of
chronic myeloid leukemia [2]. This was continued until
the introduction of busulphan in 1953. Until recently the
use of arsenical compounds was limited to the use of
organic arsenical, “melarsoprol,” in the treatment of
trypanosomiasis. In the 1970s, As2O3 was introduced
into the treatment of acute promyelocytic leukemia
(APML) in China and was found to be extremely effec-
tive in treating this condition [3]. Two patients, the first
in 1989, with APML who had relapsed following stan-
dard chemotherapy at our institution have been treated
with an Ayurvedic preparation containing arsenic. These
patients had shown a good response to the therapy they
received. One of these patients continues to remain in
complete remission (CR), five years after stopping his
therapy, though he has severe arsenic keratosis and has
recently developed cutaneous squamous cell carcinoma.
Subsequently there have been numerous other reports,
both in vitro and in vivo, which have established the
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effectiveness of As2O3 in the treatment of APML [3–12].
The majority of the available data refers to patients with
relapsed APML treated with arsenic trioxide [7, 9–17].
Few studies have addressed the role of arsenic trioxide in
the treatment of newly diagnosed cases [12], there is
limited follow-up data in these series, and therapy fol-
lowing achievement of CR is varied. The clinical expe-
rience with this drug, potential adverse effects, and its
position in the algorithm in the therapy of acute promy-
elocytic leukemia is still being defined. The optimum
cumulative dose that will maximize the beneficial effect
with respect to disease-free survival and minimize long-
term side effects remains to be determined.
In this article, we present our clinical experience and
outcome in the treatment of newly diagnosed cases of
APML with arsenic trioxide as a single agent for both
induction and consolidation.
PATIENTS AND METHODS
A trial using arsenic trioxide as a single agent in newly
diagnosed cases of APML, both in induction and con-
solidation, was initiated in January 1998 at our institu-
tion. This was an open, non-randomized single-center
study. The study was reviewed and approved by the in-
stitution’s research and ethics committee. Fourteen pa-
tients were recruited by July 2000, and they are analyzed
in this article. Patients were included in this trial if they
were diagnosed to have APML, morphologically on FAB
criteria. This was sufficient to initiate therapy with arse-
nic trioxide, but the diagnosis had to be subsequently
confirmed by karyotyping or by reverse transcriptase
polymerase chain reaction assay (RT-PCR) for promy-
elocytic leukemia and retinoic acid (RA) receptor  fu-
sion (PML-RAR) transcripts in order to be included in
the analysis.
The other inclusion criteria were that all these patients
would have in the absence of this study received pallia-
tive therapy, due to the lack of resources to support stan-
dard chemotherapy. Exclusion criteria included (1)
women who were pregnant; (2) patients who are <10
years of age; and (3) patients who were >55 years of age.
Patients who fit the above criteria were admitted by
one of the clinical investigators after the details of this
trial were explained and written informed consent had
been obtained.
One exception to the above criteria was made when a
7-year old child was included into this trial on a com-
passionate basis.
Intravenous Arsenic Trioxide
This was prepared by dissolving specified quantities of
arsenic trioxide (As2O3 AR grade [99.8% purity] from
SD Fine Chemicals Ltd, Boisar, India) in sterile pyrogen-
free distilled water at 60°C for 20 min. No other additives
were used in its preparation. The final product had a
concentration of 1 mg/mL and was supplied as 10-mL vials.
Treatment With Arsenic Trioxide
Arsenic trioxide (10 mg/10 mL) was diluted in 500 mL
of dextrose saline and infused intravenously over 3 hr
once a day. The protocol used for induction and subse-
quent consolidation is summarized on Table II.
Because one of our patients was a 7-year old child, a
dose modification of 5 mg/day was made in this case for
the entire protocol.
The initial induction course was continued till the pa-
tient had an ANC > 1.5 × 109/mm3 and platelet count
>100,000/mm3. Once this was achieved, the bone mar-
row was observed; if it was in CR (blasts + promyelo-
cytes <5% in normocellular to mildly hypocellular mar-
row), then arsenic trioxide was discontinued; if not in
CR, it was continued for an additional week and the bone
marrow was observed again at the end of the week. The
time taken to reach the above parameters was taken as the
time to achieve CR. This would be continued for a maxi-
mum period of 75 days, following which the patient
would be considered a non-responder/partial responder
and excluded from the trial.
Supportive Care
During induction, complete blood counts were done on
alternate days. Coagulation parameters were also mea-
sured on alternate days initially; this included a pro-
thrombin time (PT), activated partial thromboplastin time
(aPTT), and thrombin time (TT). Once the patient was
clinically stable, platelet count was >50,000/mm3, and
more than three serial readings of his coagulation param-
eters were normal, then the frequency of testing was
reduced to once a week.
Platelet concentrates were transfused to maintain a
platelet count >20,000/mm3 and fresh frozen plasma (15
mL/kg) was infused if the PT or aPTT were deranged.
Cryoprecipitate was infused if the TT was prolonged as
well. Packed red cell transfusions were infused to main-
tain a hemoglobin level above 8 g %. Antibiotics were
administered for fever as required.
Liver function tests were done prior to initiating
therapy, followed by biweekly and subsequently monthly
until completion of therapy.
Hydroxyurea was administered to control leucocytosis
if required as per the guidelines laid out in the protocol
on Table II. One patient was administered daunorubicin
when she developed a rapid rise in leucocytes associated
with features of an ATRA syndrome.
RT-PCR
RT-PCR analysis for PML-RAR fusion transcripts
was done according to established protocols [18]. RT-
PCR analysis was to be done at diagnosis, at first CR, at
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the start of consolidation and at the start of the 2nd, 4th,
and 6th maintenance courses. Following this, analysis
was to be done at intervals of 3 months for the first year
after completion of therapy. The RT-PCR used had a
sensitivity of 1 in 105.
RESULTS
Seventeen patients during this period were eligible to
participate in the trial. Two were excluded at the onset:
one patient was terminally ill and was excluded by the
investigators, and another refused to give consent and
opted for palliation. The remaining 15 patients were ini-
tially included on the basis of FAB criteria, but one pa-
tient was then excluded because neither the karyotype
nor the RT-PCR was consistent with a diagnosis of
APML. Fourteen patients were finally enrolled in this
study.
The clinical details, blood counts, lactic dehydroge-
nase (LDH) level, coagulation parameters, and bone mar-
row findings at diagnosis of patients enrolled in this
study are summarized on Table I. The details of the time
taken to achieve CR, additional hydroxyurea used, cu-
mulative doses of arsenic trioxide, and status at last fol-
low up are summarized on Table III.
Three patients died of intra-cerebral hemorrhage: two
on day 3 and one on day 4. Ten out of 11 patients evalu-
able for response achieved CR (91%), but one patient had
uncontrolled sepsis and died on day 21 of an intra-
cerebral bleed. The overall CR rate was 11/14 [71.4%].
Among the 10 patients who achieved CR, the average
time to CR was 52.3 days (range: 34–70 days) and the
median cumulative dose during the initial induction
therapy was 493 mg (215–700 mg). Five of these patients
have completed the scheduled course of therapy as given
on Table II. Among the remaining 5 patients, 3 are on
their maintenance schedule (one each having completed
4, 3, and 1 course of maintenance therapy), one patient
has completed the consolidation course, and one patient
has just completed the induction course.
One patient, a 19-year-old male, achieved CR with the
initial induction course of arsenic trioxide; he subse-
quently received his consolidation therapy uneventfully
as per the protocol and was then started on his mainte-
nance therapy. Prior to the initiation of the second of his
monthly maintenance schedules, he complained of a mild
nonspecific headache. Peripheral blood counts and bone
marrow were normal. Cerebrospinal fluid analysis re-
vealed a leucocyte count of 200/mm3 with 98% abnormal
promyelocytes. The presence of the bcr-1 transcript of
the PML-RAR fusion gene was confirmed in these cells
by RT-PCR. He was treated with triple intrathecal che-
motherapy consisting of methotrexate 12.5 mg, cytosine
40 mg, and hydrocortisone 50 mg (administered twice a
week for 6 weeks), cranial irradiation (24 Grays in 12
fractions), and an additional 4-week course of intrave-
nous As2O3, administered simultaneously. At the end of
this period, his CSF analysis was normal. Blood and
bone marrow evaluation repeated at the end of this course
continued to be in remission. He subsequently received
TABLE I. Baseline Characteristics
Patient no. Age/sex
Hb
(g %)
TC
(×109/L)
Plat
(×109/L)
LDH
(U/L)
PTa
Pt/control
aPTTb
Pt/control Bone marrow (B+PM)c
1 19/M 5.3 2.8 15 383 16.5/15 26.4/27 Imprints replaced by B+PM
2 27/M 10 3.7 8 1,219 17/14 25/30 95% B+PM
3 16/M 4.5 6.7 2 892 18/15 43/29 59% B+PM
4 28/F 9.4 1.4 47 378 14.6/14 23.9/28 66% B+PM
5 14/F 3.7 1.6 16 481 10.1/10 31/28 79% B+PM
6 21/F 11 1.2 12 403 10.2/11 18.9/30 37% B+PM
7 46/F 5.7 0.5 30 640 12.5/11 30.6/30 Imprints with 65% B+PM
8 28//M 7.1 1.9 20 708 12.3/11.4 33/29 53% B+PM
9 14/F 6.1 1.9 89 561 12/11.5 28/29.6 Imprints replaced by B+PM
10 17/F 14 6.7 20 1,520 17.6/11.2 33/30 Imprints with 55% B+PM
11 33/F 10 20.2 11 760 18.5/11.6 42/30 64% B+PM
12 30/M 9.7 21 17 2,000 17/10 59/30 Imprints with 85% B+PM
13 7/F 9.5 9.8 2 493 12.6/11.7 23.8/28 90% B+PM
14 15/F 6 5.8 14 668 11/10 33/31 80% B+PM
aPT, prothrombin time.
baPTT, activated partial thromboplastin time.
cB+PM, blasts + promyelocytes.
TABLE II. Arsenic Trioxide Study Protocol
Induction: As2O3 10 mg/day till CR (max 75 days)
4 weeks rest
Consolidation:a As2O3 10 mg/day × 4 weeks
4 weeks rest
Maintenance:a As2O3 10 mg/day × 10 days, once a month × 6 months
Guidelines for administration of hydroxyurea during induction
WBC <5000/mm3 No hydroxyurea
WBC >5000–10,000/mm3 500 mg od
WBC >10,000–15,000/mm3 500 mg bd
WBC >15,000–20,000/mm3 500 mg tid
WBC >20,000–50,000/mm3 500 mg qid
WBC >50,000/mm3 1.0 g qid
aAdministered if in CR.
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the next 4 monthly cycles of As2O3 as per the initial
protocol. Seventeen months have elapsed since his last
course of As2O3, and he continues to remain in complete
molecular remission.
The remaining patients have all been in continu-
ous CR.
Hyperleukocytosis and ATRA-like Syndrome
Seven of these 10 (70%) patients had a hyperleukocy-
tosis response as defined by a count >10 × 109/mm3
following initiation of therapy with arsenic trioxide. Fig-
ure 1a,b illustrates the white cell count seen among pa-
tients with and without a leukocytic response to arsenic
trioxide, while Fig. 2 illustrates the average white cell
response among these patients. One patient who received
daunorubicin during induction and had a leukocytic re-
sponse is not included in the above figures. All patients
who developed leucocytosis received additional hy-
droxyurea as per the protocol. Hydroxyurea was admin-
istered for an average of 10.5 days (range: 2–21 days)
and a median cumulative dose of 13.5 g (range: 3–40.5
g). One patient developed significant leucocytosis (maxi-
mum 61 × 109/mm3) associated with features similar to a
retinoic acid syndrome [19] with pulmonary interstitial
infiltrates, tachypnea, pleural effusion, pedal edema, and
fever. This patient was administered daunorubicin 40
mg/day on day 6 and day 7 of her induction therapy, and
arsenic trioxide was temporarily stopped for 4 days as
well. Arsenic trioxide was restarted after 4 days, and the
rest of her therapy was uneventful. No other anti-mitotic
agents were used in any of these patients.
Other Adverse Effects of Arsenic Trioxide
Adverse effects were minimal and warranted tempo-
rary discontinuation in only one patient who developed
features suggestive of a retinoic acid syndrome. Most
side effects documented were transient and did not re-
quire any intervention (Table IV). At the end of their
therapy, all five patients who completed their course of
arsenic trioxide had normal electrocardiogram, echocar-
diogram, and nerve conduction studies. This included
one patient who had severe paresthesias, which war-
ranted therapy with amitriptyline, and had evidence of
conduction defects in an earlier nerve conduction study.
All 10 patients who achieved hematological CR with
arsenic trioxide including the patient who had an isolated
CNS relapse and went into a second remission have re-
mained in continuous CR, at a median follow up of 15
months (range: 2–33 months). Although it was initially
intended that RT-PCR samples be taken at regular inter-
vals, this was not feasible due to intermittent availability
of this facility in the early phase of the trial. Hence it is
not possible to determine the time frame in which mo-
lecular remission is achieved. The results of all the RT-
PCR samples that were taken from these patients are
illustrated in Fig. 3. All patients who completed therapy
are in molecular remission. Among the patients still re-
ceiving their scheduled course of arsenic trioxide, 3/5 are
in molecular remission, while 2/5 are still positive for the
PML-RAR fusion product (Fig. 3). Of the two who are
positive, one patient has just completed induction and the
second has completed induction and consolidation.
DISCUSSION
In this series of patients we have established the effi-
cacy of arsenic trioxide as a single agent both in induc-
tion and consolidation for the management of newly di-
agnosed cases of APML. From a MEDLINE search, four
TABLE III. Summary of Response to As2O3, Time to CR, Status at Last Follow Up, and Cumulative Doses of As2O3 and
Hydroxyurea Used*
Patient no.
Response
to As2O3
Days
to CR
Completed
therapy
Status at
last follow up
Cumulative dose
of As2O3 (mg)
Hydroxyurea used
in induction
Hydroxyurea
days [cumulative dose]
1 CR 70 Yes CR 1,760a Yes 21 days [40.5 g]
2 Early death NA NA Died 30 No NA
3 Early death NA NA Died 200 No NA
4 CR 50 Yes CR 1,380a No NA
5 CR 60 Yes CR 1,480a Yes 4 days [2.5 g]
6 CR 52 Yes CR 1,400a Yes 11 days [14 g]
7 CR 34 Yes CR 1,220a No NA
8 CR 55 No CR on Rx 1,230 Yes 11 days [11.5 g]
9 CR 47 No CR on Rx 950 No NA
10 Early death NA NA Died 40 No NA
11 CR 58 No CR on Rx 880 Yes 2 days [3 g]b
12 Early death NA NA Died 40 No NA
13 CR 43 No CR on Rx 355 Yes 15 days [15.5 g]
14 CR 54 No CR on Rx 540 Yes 10 days [8 g]
*NA, not applicable; CR, complete remission.
CR on Rx, complete remission on treatment.
aCompleted therapy.
bReceived daunorubicin.
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other major trials [7,10–12] and a few case reports [14–
17] in which arsenic trioxide was used in the treatment of
APML were found. These trials and case reports pre-
dominantly involved patients with relapsed APML. The
earliest clinical data available on the use of arsenic tri-
oxide in the treatment of acute promyelocytic leukemia
are from Zhang et al. [9] and Sun et al. [13]. In these
studies, the CR rate achieved varied from 65.6% to 84%,
and long-term survival (>10 years) was seen in 9/32 pa-
tients in another study [10].
Consolidation therapy following achievement of CR
has not been addressed in most of these studies. The
study by Niu et al. [12] has addressed this issue, with
respect to the currently used schedules, and they have
clearly demonstrated that chemotherapy following remis-
sion induction is significantly superior to consolidation
with arsenic trioxide as a single agent [12]; however, the
optimal cumulative dose, if it exists, is yet to be defined.
In the present series we have used arsenic trioxide as
a single agent both for induction and consolidation. Hy-
droxyurea was also used during induction alone to con-
trol the leukocytosis seen in a proportion of patients. In
only one patient was additional daunorubicin used in
induction due to the development of a retinoic acid-like
syndrome.
Of the 11 patients evaluable for response to therapy,
10 achieved CR (91%) while one patient died on day 21
secondary to uncontrolled sepsis.
It is of interest to note that all patients in this study
who completed their scheduled course of arsenic trioxide
have also achieved molecular remission. Among the pa-
tients still on treatment, three at 5, 7, and 10 months since
diagnosis are in molecular remission while two are still
positive for the PML-RAR transcript at 2 and 3 months
since diagnosis. Although we had initially planned to do
RT-PCR on a regular basis, this was not possible due to
the intermittent availability of this test in the early phase
of this trial. Hence, though we know that almost all pa-
tients who achieve CR will eventually achieve molecular
remission with this therapy, the exact time frame in
which this happens is not known. We are evaluating this
issue in this ongoing trial.
Another interesting aspect of therapy with As2O3 is the
variable leukocytic response in patients treated with this
Fig. 1. (a) Leucocytosis seen follow-
ing initiation of arsenic trioxide in 6
patients. An additional patient who re-
ceived daunorubicin for a retinoic acid-
like syndrome and also had leucocyto-
sis is not included. (b) Three patients
who received arsenic trioxide and went
into complete remission who did not
have leucocytosis.
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drug: approximately 30%–50% have leukocytosis fol-
lowing the initiation of therapy, while in the remainder
this effect is not seen. The significance of this differential
response is not clear. An “ATRA-like syndrome” [19]
has been reported in 8 patients (31%), in the study by
Chamacho et al. [20]. Most other series have not reported
an ATRA-like syndrome with arsenic, and in the present
series it was seen in only one patient in spite of 70% of our
patients having a leukocytic response to arsenic trioxide.
Our observation in patients with the hypergranular
variant of APML who have a leukocytosis following ini-
tiation of therapy is that they have a triphasic response:
initial leucopenia at diagnosis followed by leucocytosis
and, prior to achieving CR, a second phase of leucopenia
(Figs. 1a and 2). The patients who do not have a leuko-
cytic response have a prolonged leucopenia, although the
proportion of neutrophils steadily improves and the leu-
copenia corrects in 30–50 days (Fig. 1b).
One patient developed an isolated CNS relapse during
the course of maintenance therapy [21]. It has been ob-
served that CNS relapse with APML is extremely rare,
especially in the pre-ATRA era [22–25]. Following the
use of ATRA, there has been some concern about the
increase in incidence of extramedullary and CNS re-
lapses. The increase incidence of extramedullary relapses
following the use of ATRA is believed to be due to the
up regulation of cellular and endothelial adhesion mol-
ecules [23,26]. More recently it has been demonstrated
that the differentiation induced by ATRA promoted the
acquisition of 2-integrin-dependent firm adherence and
transmigration of the promyelocytes through the endo-
thelium [27]. It was thus hypothesized that ATRA-
mediated differentiation could favor migration of differ-
entiating blasts into skin, CNS, and other tissues,
resulting in a reservoir of viable blasts. These could pro-
liferate at a latter date. While the exact mechanism by
which As2O3 induces remission is uncertain, it appears
that a similar differentiation effect as that seen with
ATRA occurs with As2O3. It is possible that a similar
up-regulation of adhesion molecules, as seen with ATRA
therapy, occurs with the use of As2O3. It has also been
demonstrated in animal experiments that the choroid plexus
protects the brain against toxic metals, such as arsenic, by
concentrating the metal up to 40 times higher within the
choroid plexus, thereby reducing the levels in the brain and
cerebrospinal fluid [28]. These two mechanisms could theo-
retically contribute to an increased incidence of CNS re-
lapses in patients treated with arsenic trioxide. This could
be of some concern in future protocols that would utilize
arsenic trioxide in the treatment of APML.
The usual toxicity seen with standard chemotherapy,
such as myelosuppression, hair loss, severe vomiting,
and exacerbation of the underlying coagulopathy, were
not seen with this therapy. Of concern was the recent
publication by Niu et al. [12], in which 58 patients with
TABLE IV. Summary of Adverse Events Attributable to
Arsenic Trioxide Among 10 Evaluable Patients
Adverse event n [%]
Skin
Mild pigmentary changes 5 [50]
Dry skin 1 [10]
Gastrointestinal tract
Decreased appetite 1 [10]
Nausea 1 [10]
Peripheral nervous system
Mild paresthesias 3 [30]
Severe paresthesiasa 1 [10]
Hepatic
Increased alkaline phospahatase 1 [10]
Mild increase in enzymes [<2-fold] 1 [10]
Retinoic acid syndrome 1 [10]
Weight gain [>10 kg] 3 [30]
Others
Achilles tendonitis 1 [10]
Somnolence 1 [10]
Conjunctival suffusion 1 [10]
aNCI common toxicity criteria grade 3. All other adverse events docu-
mented on this table were NCI-CTC grade 1.
Fig. 2. Average white cell count among 9 pa-
tients who received arsenic trioxide as a single
agent until complete remission. A triphasic re-
sponse is noted: leucopenia at diagnosis, fol-
lowed by leucocytosis and a second phase of leu-
copenia before normalization of the white cell
count.
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APML, 11 newly diagnosed and 47 relapsed cases, were
treated with As2O3. In these two groups, CR was
achieved in 72.7% and 85.1% of cases, respectively.
However, in 7/11 (63.6%) of the newly diagnosed pa-
tients with APML there was evidence of hepatic toxicity,
which included two deaths. In the group of relapsed pa-
tients, one-third of the cases had evidence of hepatic
toxicity. On the basis of this data, the authors had rec-
ommended that this drug should not be used in initial
therapy and should be reserved only for patients who
relapsed following standard chemotherapy. This data is
in contrast to our own experience with this drug and other
published data [7,10,11,15], where a similar hepatic tox-
icity profile was not seen.
The lethal dose recorded in the literature is a single
dose of more than 100 mg [10]. At the relatively small
doses used in the treatment of APML, the toxicity profile
has been favorable with acceptable acute complications;
however, chronic complications at these doses are yet to
be defined. An issue of some concern is the possibility of
late secondary malignancies as a result of chronic expo-
sure to arsenic, as seen in one of our earlier patients
treated with a prolonged course of arsenic-based Ayur-
vedic medications.
In vitro data suggest that there could be permanent
defects related to inhibition of methylation of DNA [29]
and large deletional mutations related to the generation
of reactive oxygen species [30].
The mechanism by which arsenic trioxide induces re-
mission in APML is still under evaluation. Some of the
hypothesized mechanisms include induction of apoptosis
in APL (NB4) cell lines by down-regulation of Bcl-2 [3],
increased expression of cysteine proteases [7], reorganiz-
ing a nuclear organelle known as the PML oncogenic
domain (POD), which is disrupted following the PML-
RAR fusion or through activation of the Jun kinases in
a p53-independent pathway [31]. Arsenic compounds
also bind to sulfhydryl-rich proteins/enzymes and affect
their function. Important in this group is glutathione; re-
duction in its level could lead to increase oxidative stress,
DNA damage, and result in apoptosis [32,33]. Differen-
tiation similar to that seen with ATRA, especially at low
doses probably by degradation of the PML-RAR fusion
product [4], has also been reported. No single mechanism
can explain all the effects seen with arsenic trioxide; it
probably acts at multiple levels, and this effect can vary
with the concentration of the drug. Additional factors are
still being defined, and understanding these could be cru-
cial in maximizing efficacy while reducing toxicity.
Fig. 3. Each line adjacent to the serial number on the y axis illustrates the duration of follow up of each of these patients.
Symbols on these lines indicate times at which samples for RT-PCR were taken. Solid arrows indicate RT-PCR positive. At
diagnosis RT-PCR was positive in 13 patients, while in one patient a sample was not available [this patient’s karyotype was
positive for t(15;17)]. Open arrows indicate RT-PCR negative. Eight out of the 10 patients who are alive are in molecular
remission. Solid ovals indicate deaths: 4 patients died, and all were early deaths.
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While there is no doubt as to the efficacy of As2O3 in
the management of APML, its position in the algorithm
of treatment for APML is yet to be defined. For patients
who cannot afford standard chemotherapy as in the pres-
ent series, the role of As2O3 as a single agent for induc-
tion remission and consolidation has been addressed and
has been found to be very effective when used in the
present schedule.
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